{"product_id":"glp-1-gip","title":"GIP\/GLP-1","description":"\u003cdiv class=\"strapi-description text-sm text-[#4B5563] md:text-base line-clamp-6\"\u003e\n\u003cp\u003eGLP-1\/GIP research compound. Supplied as a lyophilized peptide for laboratory research applications.\u003c\/p\u003e\n\u003cp\u003ePurity-tested per lot.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFor laboratory research use only. Not for human or veterinary use.\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/div\u003e\u003cdiv class=\"container px-3\"\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"Characteristics\" id=\"characteristics\"\u003eCharacteristics\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eMolecular Formula\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eC225H348N60O68\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eCAS\tNumber\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003e2023788-19-2\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eMolar Mass\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003e5047.61 g\/mol\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eAmino Acid Sequence\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eHis-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eSynonyms\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003e LY3298176\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eSolubility\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eWater-soluble\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eOrganoleptic Profile\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eWhite to off-white powder\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eComposition\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eLyophilized powder - requires reconstitution\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"How Is GIP\/GLP-1 Studied?\" id=\"how-is-gipglp-1-studied\"\u003eHow Is GIP\/GLP-1 Studied?\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\u003cp style=\"line-height:1.38;margin-bottom:12pt;margin-top:0pt;\" dir=\"ltr\"\u003e\u003cspan style=\"background-color:transparent;color:#000000;font-family:Arial,sans-serif;font-size:11pt;\"\u003e\u003cspan style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003eGIP\/GLP-1 is a synthetic peptide analog that has been investigated in preclinical laboratory research for its interaction with key receptors involved in metabolic signaling pathways. Specifically, it targets the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. These receptors are found in various mammalian tissues and play a role in cellular communication and metabolic function.\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"Research Context\" id=\"research-context\"\u003eResearch Context\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\n\u003cp style=\"line-height:1.38;margin-bottom:12pt;margin-top:0pt;\" dir=\"ltr\"\u003e\u003cspan style=\"background-color:transparent;color:#000000;font-family:Arial,sans-serif;font-size:11pt;\"\u003e\u003cspan style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003eEmerging clinical studies have evaluated the investigational use of GIP\/GLP-1 in adults with type 2 diabetes and related metabolic conditions\u003c\/span\u003e\u003cspan style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e\u003cstrong\u003e.\u003c\/strong\u003e\u003c\/span\u003e\u003cspan style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e Findings from these trials suggest potential effects on multiple health indicators:\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cul style=\"margin-bottom:0;margin-top:0;padding-inline-start:48px;\"\u003e\n\u003cli style=\"background-color:transparent;color:#000000;font-family:Arial,sans-serif;font-size:11pt;font-style:normal;font-variant:normal;font-weight:400;list-style-type:disc;text-decoration:none;vertical-align:baseline;white-space:pre;\" dir=\"ltr\" aria-level=\"1\"\u003e\u003cspan style=\"background-color:transparent;color:#000000;font-family:Arial,sans-serif;font-size:11pt;\"\u003e\u003cspan style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e\u003cstrong\u003eGlycemic Measures\u003c\/strong\u003e\u003c\/span\u003e\u003cspan style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e: GIP\/GLP-1 has been linked to reductions in HbA1c and improvements in fasting and postprandial blood glucose levels\u003c\/span\u003e\u003cspan style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e\u003cstrong\u003e \u003c\/strong\u003e\u003c\/span\u003e\u003cspan style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003ecompared with placebo or alternative therapies.\u003c\/span\u003e\u003c\/span\u003e\u003c\/li\u003e\n\u003cli style=\"background-color:transparent;color:#000000;font-family:Arial,sans-serif;font-size:11pt;font-style:normal;font-variant:normal;font-weight:400;list-style-type:disc;text-decoration:none;vertical-align:baseline;white-space:pre;\" dir=\"ltr\" aria-level=\"1\"\u003e\u003cspan style=\"background-color:transparent;color:#000000;font-family:Arial,sans-serif;font-size:11pt;\"\u003e\u003cspan style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e\u003cstrong\u003eBody Weight\u003c\/strong\u003e\u003c\/span\u003e\u003cspan style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e: Some studies have reported weight changes in participants with overweight or obesity\u003c\/span\u003e\u003cspan style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e\u003cstrong\u003e, \u003c\/strong\u003e\u003c\/span\u003e\u003cspan style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003ewith outcomes varying by dose.\u003c\/span\u003e\u003c\/span\u003e\u003c\/li\u003e\n\u003cli style=\"background-color:transparent;color:#000000;font-family:Arial,sans-serif;font-size:11pt;font-style:normal;font-variant:normal;font-weight:400;list-style-type:disc;text-decoration:none;vertical-align:baseline;white-space:pre;\" dir=\"ltr\" aria-level=\"1\"\u003e\u003cspan style=\"background-color:transparent;color:#000000;font-family:Arial,sans-serif;font-size:11pt;\"\u003e\u003cspan style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e\u003cstrong\u003eCardiovascular Indicators\u003c\/strong\u003e\u003c\/span\u003e\u003cspan style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e: Research has shown possible improvements in lipid markers such as triglycerides and LDL cholesterol, along with modest effects on blood pressure\u003c\/span\u003e\u003cspan style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e\u003cstrong\u003e.\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/li\u003e\n\u003cli style=\"background-color:transparent;color:#000000;font-family:Arial,sans-serif;font-size:11pt;font-style:normal;font-variant:normal;font-weight:400;list-style-type:disc;text-decoration:none;vertical-align:baseline;white-space:pre;\" dir=\"ltr\" aria-level=\"1\"\u003e\u003cspan style=\"background-color:transparent;color:#000000;font-family:Arial,sans-serif;font-size:11pt;\"\u003e\u003cspan style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e\u003cstrong\u003eRenal Markers\u003c\/strong\u003e\u003c\/span\u003e\u003cspan style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e: Early findings indicate potential influence on kidney function markers\u003c\/span\u003e\u003cspan style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e\u003cstrong\u003e,\u003c\/strong\u003e\u003c\/span\u003e\u003cspan style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e including albuminuria, though long-term outcomes remain under study.\u003c\/span\u003e\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp style=\"line-height:1.38;margin-bottom:12pt;margin-top:12pt;\" dir=\"ltr\"\u003e\u003cspan style=\"background-color:transparent;color:#000000;font-family:Arial,sans-serif;font-size:11pt;\"\u003e\u003cspan style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003eThese results are derived from controlled research settings and may not apply to all populations.\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"Side Effects\" id=\"side-effects\"\u003eSide Effects\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\n\u003cp style=\"line-height:1.38;margin-bottom:12pt;margin-top:0pt;\" dir=\"ltr\"\u003e\u003cspan style=\"background-color:transparent;color:#000000;font-family:Arial,sans-serif;font-size:11pt;\"\u003e\u003cspan style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003eIn clinical trials, participants receiving GIP\/GLP-1 analogs have reported a range of adverse events\u003c\/span\u003e\u003cspan style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e\u003cstrong\u003e.\u003c\/strong\u003e\u003c\/span\u003e\u003cspan style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e The most commonly observed include:\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cul style=\"margin-bottom:0;margin-top:0;padding-inline-start:48px;\"\u003e\n\u003cli style=\"background-color:transparent;color:#000000;font-family:Arial,sans-serif;font-size:11pt;font-style:normal;font-variant:normal;font-weight:400;list-style-type:disc;text-decoration:none;vertical-align:baseline;white-space:pre;\" dir=\"ltr\" aria-level=\"1\"\u003e\u003cspan style=\"background-color:transparent;color:#000000;font-family:Arial,sans-serif;font-size:11pt;\"\u003e\u003cspan style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e\u003cstrong\u003eGastrointestinal issues\u003c\/strong\u003e\u003c\/span\u003e\u003cspan style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e such as nausea, vomiting, or diarrhea\u003c\/span\u003e\u003c\/span\u003e\u003c\/li\u003e\n\u003cli style=\"background-color:transparent;color:#000000;font-family:Arial,sans-serif;font-size:11pt;font-style:normal;font-variant:normal;font-weight:400;list-style-type:disc;text-decoration:none;vertical-align:baseline;white-space:pre;\" dir=\"ltr\" aria-level=\"1\"\u003e\u003cspan style=\"background-color:transparent;color:#000000;font-family:Arial,sans-serif;font-size:11pt;\"\u003e\u003cspan style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e\u003cstrong\u003eInjection site reactions\u003c\/strong\u003e\u003c\/span\u003e\u003cspan style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e (pain, redness, or itching)\u003c\/span\u003e\u003c\/span\u003e\u003c\/li\u003e\n\u003cli style=\"background-color:transparent;color:#000000;font-family:Arial,sans-serif;font-size:11pt;font-style:normal;font-variant:normal;font-weight:400;list-style-type:disc;text-decoration:none;vertical-align:baseline;white-space:pre;\" dir=\"ltr\" aria-level=\"1\"\u003e\u003cspan style=\"background-color:transparent;color:#000000;font-family:Arial,sans-serif;font-size:11pt;\"\u003e\u003cspan style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e\u003cstrong\u003eHypoglycemia (low blood sugar)\u003c\/strong\u003e\u003c\/span\u003e\u003cspan style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e, especially when combined with insulin or sulfonylureas\u003c\/span\u003e\u003c\/span\u003e\u003c\/li\u003e\n\u003cli style=\"background-color:transparent;color:#000000;font-family:Arial,sans-serif;font-size:11pt;font-style:normal;font-variant:normal;font-weight:400;list-style-type:disc;text-decoration:none;vertical-align:baseline;white-space:pre;\" dir=\"ltr\" aria-level=\"1\"\u003e\u003cspan style=\"background-color:transparent;color:#000000;font-family:Arial,sans-serif;font-size:11pt;\"\u003e\u003cspan style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e\u003cstrong\u003eIncreased heart rate\u003c\/strong\u003e\u003c\/span\u003e\u003cspan style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e in some individuals\u003c\/span\u003e\u003c\/span\u003e\u003c\/li\u003e\n\u003cli style=\"background-color:transparent;color:#000000;font-family:Arial,sans-serif;font-size:11pt;font-style:normal;font-variant:normal;list-style-type:disc;text-decoration:none;vertical-align:baseline;white-space:pre;\" dir=\"ltr\" aria-level=\"1\"\u003e\u003cspan style=\"background-color:transparent;color:#000000;font-family:Arial,sans-serif;font-size:11pt;\"\u003e\u003cspan style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e\u003cstrong\u003eRare allergic reactions\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"Summary\" id=\"summary\"\u003eSummary\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\u003cp\u003e\u003cspan style=\"background-color:transparent;color:#000000;font-family:Arial,sans-serif;font-size:11pt;\"\u003e\u003cspan style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003eGIP\/GLP-1 is a synthetic peptide analog studied in preclinical models for its interaction with GIP and GLP-1 receptors, which are central to metabolic and hormonal signaling pathways. Laboratory research has examined its effects on glucose metabolism, insulin signaling, and endocrine regulation. These investigations are performed in non-human or \u003c\/span\u003e\u003ci\u003e\u003cspan style=\"font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003ein vitro\u003c\/span\u003e\u003c\/i\u003e\u003cspan style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline;white-space:pre-wrap;\"\u003e settings and do not represent established safety or efficacy in humans. Ongoing research continues to evaluate its biological activity and potential clinical applications across metabolic and endocrine studies.\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"References\" id=\"references\"\u003eReferences\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\n\u003col\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36498958\/\"\u003eGentilella R, Pechtner V, Corcos A, Consoli A. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?. Diabetes Metab Res Rev. 2019\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38591071\/\"\u003eSamms RJ, Coghlan MP, Sloop KW. How May GIP Enhance the Therapeutic Efficacy of GLP-1?. Trends Endocrinol Metab. 2020\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38584893\/\"\u003eCoskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38555463\/\"\u003eFrias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38551786\/\"\u003eFrias JP, Nauck MA, Van J, et al. Efficacy and tolerability of GLP-1\/GIP, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab. 2020\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38549766\/\"\u003eFrias JP, Davies MJ, Rosenstock J, et al. GLP-1\/GIP versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38547961\/\"\u003eRosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist GLP-1\/GIP in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38531211\/\"\u003eLudvik B, Giorgino F, Jódar E, et al. Once-weekly GLP-1\/GIP versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38531038\/\"\u003eDel Prato S, Kahn SE, Pavo I, et al. GLP-1\/GIP versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38530948\/\"\u003eDahl D, Onishi Y, Norwood P, et al. Effect of Subcutaneous GLP-1\/GIP vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c!--$!--\u003e\u003ctemplate data-dgst=\"BAILOUT_TO_CLIENT_SIDE_RENDERING\"\u003e\u003c\/template\u003e\n  \u003cdiv data-scroll-name=\"Certificate of Analysis (COA)\" class=\"\"\u003e\n  \u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\n    \u003ch2 class=\"mb-6 text-2xl font-semibold leading-[2.25rem] tracking-tight md:my-0\" id=\"certificates\"\u003e\n      Certificate of Analysis (COA)\n    \u003c\/h2\u003e\n  \u003c\/div\u003e\n\n  \u003cdiv class=\"flex w-full flex-row flex-wrap gap-x-0 gap-y-4 md:gap-x-8\"\u003e\n  \n    \u003cdiv class=\"w-1\/2 md:w-fit\"\u003e\n      \u003cdiv class=\"relative overflow-hidden rounded-none\"\u003e\n\t\t\u003ca href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0971\/5731\/6908\/files\/GIPGLP-1-1.avif?v=1779882181\" target=\"_blank\"\u003e\n        \u003cimg alt=\"Certificate\" loading=\"lazy\" width=\"175\" height=\"227\" decoding=\"async\" data-nimg=\"1\" class=\"h-full w-full max-w-[150px] cursor-pointer rounded-none object-cover md:max-w-[175px]\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0971\/5731\/6908\/files\/GIPGLP-1-1.avif?v=1779882181\" style=\"color: transparent;\"\u003e\n\t\t\u003c\/a\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n\t\n\t\u003cdiv class=\"w-1\/2 md:w-fit\"\u003e\n      \u003cdiv class=\"relative overflow-hidden rounded-none\"\u003e\n\t\t\u003ca href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0971\/5731\/6908\/files\/GIPGLP-1-2.avif?v=1779882181\" target=\"_blank\"\u003e\n        \u003cimg alt=\"Certificate\" loading=\"lazy\" width=\"175\" height=\"227\" decoding=\"async\" data-nimg=\"1\" class=\"h-full w-full max-w-[150px] cursor-pointer rounded-none object-cover md:max-w-[175px]\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0971\/5731\/6908\/files\/GIPGLP-1-2.avif?v=1779882181\" style=\"color: transparent;\"\u003e\n\t\t\u003c\/a\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/div\u003e\n\u003c\/div\u003e\n\u003c!--\/$--\u003e\u003cdiv data-scroll-name=\"Resource\" class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" id=\"resources\"\u003eResource\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"w-full\"\u003e\u003cdiv class=\"text-base text-[#4B5563]\"\u003e\u003cspan\u003eAll products on this site are for research and development use only. Products are not for human consumption of any kind. The statements made on this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure, or prevent any disease. Power Peptides is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Power Peptides is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act. All products are sold for research, laboratory, or analytical purposes only, and are not for human consumption. Power Peptides Products are intended strictly for research purposes only. These products are not approved by the U.S. Food and Drug Administration (FDA) for human consumption or medical use. Under no circumstances should these peptides be used for any purpose other than research. By purchasing or using our peptides, you acknowledge and agree that you will use them solely in accordance with applicable laws and regulations and that you accept full responsibility for their use. Statements made on this website have not been evaluated by the USA Food and Drug Administration.\u003c\/span\u003e\u003c\/div\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"My Store","offers":[{"title":"10mg","offer_id":53240039440684,"sku":"PEP-VIL-TZP-10MG709375","price":66.99,"currency_code":"USD","in_stock":true},{"title":"15mg","offer_id":53240039473452,"sku":"PEP-VIL-TZP-15MG634558","price":77.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0971\/5731\/6908\/files\/gip_glp-1-10mg-1763388914922.png?v=1779696795","url":"https:\/\/www.powerpieeptidesus.com\/products\/glp-1-gip","provider":"Power Peptides","version":"1.0","type":"link"}